Eli Lilly Beheer
Beheer criteriumcontroles 2/4
De CEO Eli Lilly is Dave Ricks, benoemd in Jan2017, heeft een ambtstermijn van 9.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 36.70M, bestaande uit 4.6% salaris en 95.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.091% van de aandelen van het bedrijf, ter waarde $ 830.89M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.7 jaar en 9.9 jaar.
Belangrijke informatie
Dave Ricks
Algemeen directeur
US$36.7m
Totale compensatie
| Percentage CEO-salaris | 4.63% |
| Dienstverband CEO | 9.3yrs |
| Eigendom CEO | 0.09% |
| Management gemiddelde ambtstermijn | 6.7yrs |
| Gemiddelde ambtstermijn bestuur | 9.9yrs |
Recente managementupdates
Recent updates
Seeking Alpha • May 19
Eli Lilly Is A Buy (Technical Analysis)
Summary Eli Lilly exhibits strong bullish technicals, with price action, momentum, and relative strength all supporting a continued uptrend. Despite an 'F' valuation grade, LLY's growth, profitability, and upward earnings revisions reinforce its investment appeal. Recent earnings beat expectations, with Q1 EPS of $8.55 and revenue of $19.8B; 2026 guidance was raised. Institutional accumulation is evident, and I would reconsider my position only if LLY closes below its 30-week EMA. Read the full article on Seeking Alpha
Narratiefupdate • May 07
LLY: Obesity Pricing Pressure And Safety Headlines Will Shape Future Franchise Economics
Analysts have raised Eli Lilly's implied fair value from $883.99 to $899.73 after several firms increased their price targets by $1 to $50, citing confidence in the obesity and diabetes pipeline, Foundayo's regulatory progress, and clarifications around recent safety concerns. Analyst Commentary Recent research on Eli Lilly reflects a mix of enthusiasm around obesity and diabetes assets and a clearer, more cautious minority that is focused on how much optimism is already reflected in the stock.
Narratiefupdate • Apr 20
LLY: Obesity And Diabetes Platform Will Support Premium Positioning Beyond 2030
Analysts have slightly raised their average price targets on Eli Lilly in recent weeks, citing supportive trial updates in obesity and diabetes, favorable comparisons to competing GLP-1 therapies, and regulatory progress that they say supports high but unchanged fair value estimates of around $1,500. Analyst Commentary Recent Street research around Eli Lilly has been active, with a cluster of price target moves, rating changes, and product specific notes that give you a clearer sense of how professionals are framing the risk and reward.
Narratiefupdate • Apr 06
LLY: Oral GLP-1 Launch And Capacity Expansion Will Drive Future Obesity Upside
Analysts have nudged Eli Lilly's price target slightly higher by $1, reflecting updated views on obesity and diabetes franchises following recent Foundayo approval commentary and comparative GLP-1 data. Analyst Commentary Recent research on Eli Lilly clusters around obesity and diabetes, pricing dynamics in GLP-1 therapies, and the implications of new product approvals and trial readouts for long term growth and valuation.
Nieuw narratief • Mar 25
Eli Lilly: A Pipeline-Driven Growth Story Trading 30% Below What the Business Is Actually Worth
Eli Lilly already runs one of the fastest-growing drug businesses on earth, and its most powerful drug is not even approved yet. WHERE THE STOCK SITS TODAY The current price is around $907 (25/03/2026).Narratiefupdate • Mar 23
LLY: Obesity And Diabetes Franchise Strength Will Support Premium Positioning
Analysts have raised their price target for Eli Lilly to $1,500, citing updated models that reflect slightly stronger assumed revenue growth, a marginally higher profit margin profile, and continued confidence in the obesity and diabetes franchises following recent trial data and supportive sell side research. Analyst Commentary Recent research highlights a split view on Eli Lilly, with some bullish analysts leaning into the obesity and diabetes opportunity set, while at least one more cautious voice questions how much growth is already reflected in the share price.Narratiefupdate • Mar 09
LLY: Obesity Drug Leadership And Pipeline Catalysts Will Sustain Premium Positioning
The updated analyst price target for Eli Lilly has increased to $1,490.52 from $1,429.89. Analysts highlight the obesity and GLP-1 franchise, premium valuations tied to weight loss leadership, and potential upside from pipeline and acquisition catalysts as key factors supporting this change.Narratiefupdate • Feb 23
LLY: GLP-1 Obesity Leadership Will Drive Future Cardiometabolic And M&A Upside
Eli Lilly's analyst price targets have shifted higher, with our fair value estimate moving from $1,093.22 to $1,211.21, as analysts point to sustained GLP-1 obesity leadership, premium valuation support, and an expanding cardiometabolic pipeline as key drivers of their updated views. Analyst Commentary Recent Street research on Eli Lilly clusters around a few clear themes, with bullish analysts focusing on obesity leadership, cardiometabolic breadth, and M&A, while more cautious voices watch valuation and execution risk around the pipeline.Narratiefupdate • Feb 08
LLY: Government Pricing Deals Will Compress Obesity Franchise Economics Going Forward
Analysts have raised their fair value estimate for Eli Lilly from US$770 to about US$884 per share, reflecting updated assumptions on long term obesity opportunities, recent price target increases across several firms, and steady expectations around margins and future P/E multiples. Analyst Commentary The latest batch of research on Eli Lilly revolves around its weight loss and cardiometabolic franchises, expectations for new product launches, and the implications of recent policy developments on pricing and access.Analyseartikel • Feb 07
Eli Lilly and Company (NYSE:LLY) Just Released Its Yearly Earnings: Here's What Analysts Think
Investors in Eli Lilly and Company ( NYSE:LLY ) had a good week, as its shares rose 2.0% to close at US$1,058 following...Narratiefupdate • Jan 25
LLY: Government GLP 1 Pricing Deals Will Pressure Obesity Margins
Analysts have nudged their price targets on Eli Lilly slightly higher, citing continued confidence in the obesity and GLP 1 franchise, supportive government pricing agreements, and potential upside from acquisitions and pipeline catalysts, even as some firms fine tune their models and individual targets by low single digit amounts such as Guggenheim's recent US$2 trim. Analyst Commentary Recent research on Eli Lilly has been dominated by optimism around obesity treatments and government pricing agreements, but there is also a pocket of caution that is worth paying attention to if you are thinking about valuation, execution and long term growth risk.Narratiefupdate • Jan 11
LLY: GLP-1 Pricing Deals Will Pressure Obesity Margins Going Forward
Analysts lifted their fair value estimate for Eli Lilly from US$650 to US$770, citing higher assumed profit margins, a slightly higher discount rate, updated expectations for revenue growth and future P/E, and continued Street support related to the obesity franchise, GLP-1 pricing agreements, and pipeline catalysts. Analyst Commentary Recent Street research around Eli Lilly has been dominated by views on obesity drugs, pricing agreements with the U.S. government, and the company’s expanding pipeline.Narratiefupdate • Dec 27
LLY: GLP-1 Pricing Deals And Policy Will Shape Future Obesity Leadership And Risks
Analysts have lifted their fair value estimate for Eli Lilly to approximately $1,093 from about $1,024, reflecting expectations for stronger long term GLP 1 driven revenue growth, expanding profit margins and sustained leadership in the obesity market, supported by recent U.S. reimbursement and pricing deals. Analyst Commentary Street research remains broadly constructive on Eli Lilly, with a series of upward price target revisions and fresh coverage initiations underscoring confidence in the durability of its GLP 1 franchise and broader innovation pipeline.Narratiefupdate • Dec 13
LLY: Government Access Deals Will Drive Durable Obesity And Diabetes Leadership
Analysts have raised their fair value estimate for Eli Lilly shares from approximately $1,170 to about $1,430 per share, reflecting higher expected profitability and sustained leadership in the GLP 1 obesity and diabetes market, supported by recent U.S. government access deals and upcoming launches such as orforglipron. Analyst Commentary Bullish analysts continue to frame Eli Lilly as a core beneficiary of the expanding obesity and diabetes treatment market, with valuation upside tied to both higher GLP 1 penetration and a broadening metabolic pipeline.Narratiefupdate • Nov 29
LLY: Upcoming Price Discounts And Policy Decisions Will Influence Drug Market Leadership And Risks
Eli Lilly's analyst price target has increased by approximately $21 to $1,024. Analysts cite earnings upside, expanding obesity drug opportunities, and recently announced government reimbursement agreements as key drivers of improved growth and profitability expectations.Analyseartikel • Nov 25
Investors Appear Satisfied With Eli Lilly and Company's (NYSE:LLY) Prospects As Shares Rocket 30%
Despite an already strong run, Eli Lilly and Company ( NYSE:LLY ) shares have been powering on, with a gain of 30% in...
Narratiefupdate • Nov 21
GLP-1 drugs part of medicare
Short update, this is more bullish news about the demand for GLP-1 drugs in general spurring growth in this type of weight loss drug. Also, earnings report have showed that increase in earnings have been driven by increase in volume of GLP-1 drugs.Narratiefupdate • Nov 15
LLY: Upcoming Drug Price Reductions and Policy Debates Will Shape Future Opportunities and Risks
The analyst price target for Eli Lilly has increased by over $80 to approximately $1,003 per share. Analysts point to accelerating revenue growth, higher profit margins, and ongoing strength in the company's obesity drug franchise as drivers of greater long-term value.Analyseartikel • Nov 07
Eli Lilly (NYSE:LLY) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Eli Lilly and Company's ( NYSE:LLY ) stock was strong after they recently reported robust earnings. However, we think...Narratiefupdate • Nov 01
LLY: Upcoming Drug Launches And Global Expansion Will Shape Future Outlook
Eli Lilly’s fair value estimate has increased from $891.62 to $919.33. This reflects analysts' upward price target revisions following stronger than expected quarterly results and an improved earnings outlook.Nieuw narratief • Sep 19
Eli Lilly's Future Growth Driven by Tirzepatide and Favorable Market Conditions
Catalysts Mounjaro/Zepbound: Lilly’s tirzepatide franchise is the engine of growth. Mounjaro (for type 2 diabetes) and Zepbound (obesity) each grew rapidly in 2024.Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$25b |
| Dec 31 2025 | US$37m | US$2m | US$21b |
| Sep 30 2025 | n/a | n/a | US$18b |
| Jun 30 2025 | n/a | n/a | US$14b |
| Mar 31 2025 | n/a | n/a | US$11b |
| Dec 31 2024 | US$29m | US$2m | US$11b |
| Sep 30 2024 | n/a | n/a | US$8b |
| Jun 30 2024 | n/a | n/a | US$7b |
| Mar 31 2024 | n/a | n/a | US$6b |
| Dec 31 2023 | US$27m | US$2m | US$5b |
| Sep 30 2023 | n/a | n/a | US$5b |
| Jun 30 2023 | n/a | n/a | US$6b |
| Mar 31 2023 | n/a | n/a | US$6b |
| Dec 31 2022 | US$21m | US$2m | US$6b |
| Sep 30 2022 | n/a | n/a | US$6b |
| Jun 30 2022 | n/a | n/a | US$6b |
| Mar 31 2022 | n/a | n/a | US$6b |
| Dec 31 2021 | US$22m | US$2m | US$6b |
| Sep 30 2021 | n/a | n/a | US$6b |
| Jun 30 2021 | n/a | n/a | US$6b |
| Mar 31 2021 | n/a | n/a | US$6b |
| Dec 31 2020 | US$24m | US$1m | US$6b |
| Sep 30 2020 | n/a | n/a | US$6b |
| Jun 30 2020 | n/a | n/a | US$6b |
| Mar 31 2020 | n/a | n/a | US$6b |
| Dec 31 2019 | US$21m | US$1m | US$5b |
Compensatie versus markt: De totale vergoeding ($USD 36.70M ) Dave } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 14.80M ).
Compensatie versus inkomsten: De vergoeding van Dave is het afgelopen jaar met meer dan 20% gestegen.
CEO
Dave Ricks (57 yo)
9.3yrs
Tenure
US$36,698,337
Compensatie
Mr. David A. Ricks, also known as Dave, has been a Director of Adobe Inc. since April 12, 2018 and previously served as its Director since June 2017. He served as a Director of Elanco Animal Health Incorpo...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & CEO | 9.3yrs | US$36.70m | 0.091% $ 830.9m | |
| Executive VP & CFO | 1.7yrs | US$8.48m | 0.0018% $ 16.5m | |
| Chief Scientific & Product Officer and President of Lilly Research Laboratories | 7.9yrs | US$17.79m | 0.026% $ 240.1m | |
| Executive VP | 6.3yrs | US$9.85m | 0.0062% $ 56.6m | |
| Executive VP | no data | US$7.59m | 0.0041% $ 37.0m | |
| Senior VP of Finance & Chief Accounting Officer | 13.5yrs | geen gegevens | 0.00059% $ 5.4m | |
| Executive VP and Chief Information & Digital Officer | 5yrs | US$5.10m | 0.0030% $ 26.9m | |
| Director of Investor Relations | 7.5yrs | geen gegevens | geen gegevens | |
| Executive VP & Chief People Officer | 3.4yrs | geen gegevens | 0.0017% $ 15.1m | |
| Executive VP and President of Lilly USA & Global Customer Capabilities | 5.6yrs | geen gegevens | 0.0036% $ 32.9m | |
| Executive VP & President of Lilly International | 6.7yrs | US$3.92m | 0.0069% $ 62.4m | |
| Senior Vice President of Global Value & Access | 6.8yrs | geen gegevens | geen gegevens |
6.7yrs
Gemiddelde duur
51yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van LLY is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.7 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & CEO | 9.3yrs | US$36.70m | 0.091% $ 830.9m | |
| Independent Director | 5.3yrs | US$365.50k | 0.00033% $ 3.0m | |
| Chairman Emeritus | 17.3yrs | US$13.06m | geen gegevens | |
| Independent Director | 20.5yrs | US$343.80k | 0.00019% $ 1.7m | |
| Independent Director | 17.1yrs | US$361.00k | 0.000090% $ 817.7k | |
| Independent Director | less than a year | US$7.68k | 0.00022% $ 2.0m | |
| Independent Director | 13.9yrs | US$392.00k | geen gegevens | |
| Independent Director | 4yrs | US$339.00k | 0.000040% $ 363.4k | |
| Lead Independent Director | 10.3yrs | US$398.00k | 0.0019% $ 17.2m | |
| Independent Director | 14.4yrs | US$361.00k | geen gegevens | |
| Independent Director | 9.6yrs | US$368.00k | 0.000020% $ 181.7k | |
| Independent Director | 5.3yrs | US$336.00k | geen gegevens |
9.9yrs
Gemiddelde duur
63.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van LLY wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.9 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/21 21:47 |
| Aandelenkoers aan het einde van de dag | 2026/05/21 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Eli Lilly and Company wordt gevolgd door 53 analisten. 28 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Kerry Holford | Berenberg |